Clinical investigation on the hypolipidemic effect of simvastatin in primary hypercholesterolemia.
Simvastatin, 20 mg daily, was given orally to 21 hypercholesterolemic outpatients for 16 weeks. During treatment a significant reduction was found in plasma total and LDL cholesterol; plasma HDL-cholesterol levels increased during the treatment. Results indicate that simvastatin, because of its activity and lack of toxicity and side effects, can be considered a drug of first-choice for the treatment of primary hypercholesterolemia.
Saba
P
P
Department of Medicine, USL 7 Val di Nievole, Pescia.
Galeone
F
F
Giuntoli
F
F
Spagnolo
G
G
Brunelleschi
G
G
Lamanna
F
F
Angelé
B
B
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D004341:Drug Evaluation; D005215:Fasting / Q000097:blood; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019821:Simvastatin; D013997:Time Factors
D000924:Anticholesteremic Agents; D002214:Capsules; D008055:Lipids; D008148:Lovastatin; D019821:Simvastatin